Medicare Enrolled

Dr. Priya Rudolph, MD, PHD

Hematology & Oncology · Athens, GA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
125 KING AVE, Athens, GA 30606
7063694478
In practice since 2005 (20 years)
NPI: 1871587113 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rudolph from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rudolph? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rudolph

Dr. Priya Rudolph is a hematology & oncology specialist in Athens, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rudolph performed 1,766 Medicare services across 721 unique beneficiaries.

Between the years covered by Open Payments, Dr. Rudolph received a total of $645,289 from 66 pharmaceutical and/or device companies across 742 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rudolph is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 25% volume in GA $645,289 industry payments

Medicare Practice Summary

Medicare Utilization ↗
1,766
Medicare services
Top 25% in GA for hematology & oncology
721
Unique beneficiaries
$50
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~88 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
1,536 $46 $213
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
73 $72 $314
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
57 $60 $317
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
48 $100 $484
Bone marrow biopsy and aspiration
A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions.
39 $57 $530
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
13 $111 $422
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$645,289
Total received (2018-2024)
Avg $92,184/year across 7 years
Top 0% in GA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
742
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$449,563 (69.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$188,482 (29.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,244 (1.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$172,960
2023
$218,481
2022
$78,188
2021
$55,191
2020
$29,462
2019
$43,161
2018
$47,845

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$44,468
Daiichi Sankyo Inc.
$33,969
AstraZeneca Pharmaceuticals LP
$21,777
Gilead Sciences, Inc.
$21,191
PUMA BIOTECHNOLOGY, INC.
$7,443
E.R. Squibb & Sons, L.L.C.
$6,533
Lilly USA, LLC
$5,985
Stemline Therapeutics Inc.
$5,882
EMD Serono, Inc.
$5,346
Incyte Corporation
$5,310
Ipsen Biopharmaceuticals, Inc
$4,795
MorphoSys, US Inc.
$3,080
ABBVIE INC.
$2,505
BTG International, Inc.
$1,500
Celgene Corporation
$1,122
Janssen Scientific Affairs, LLC
$313
SOBI, INC
$216
Tempus AI, Inc
$189
Amgen Inc.
$180
GlaxoSmithKline, LLC.
$170
Takeda Pharmaceuticals U.S.A., Inc.
$165
Merck Sharp & Dohme LLC
$145
Adaptive Biotechnologies Corporation
$111
JAZZ PHARMACEUTICALS INC.
$93
Eisai Inc.
$79
Corcept Therapeutics
$70
Genentech USA, Inc.
$58
Janssen Biotech, Inc.
$40
Blueprint Medicines Corporation
$33
ARRAY BIOPHARMA INC
$32
Novartis Pharmaceuticals Corporation
$27
Bayer Healthcare Pharmaceuticals Inc.
$23
Genmab U.S., Inc.
$23
Agios Pharmaceuticals, Inc.
$18
Coherus Biosciences Inc.
$18
Regeneron Healthcare Solutions, Inc.
$17
PharmaEssentia USA Corporation
$16
Alexion Pharmaceuticals, Inc.
$14
Top 3 companies account for 57.9% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$132,098
AstraZeneca Pharmaceuticals LP
$96,188
Daiichi Sankyo Inc.
$89,484
Gilead Sciences, Inc.
$51,246
Stemline Therapeutics Inc.
$49,728
PUMA BIOTECHNOLOGY, INC.
$34,786
Seagen Inc.
$29,024
Puma Biotechnology, Inc.
$21,354
E.R. Squibb & Sons, L.L.C.
$17,914
GlaxoSmithKline, LLC.
$11,840
Janssen Scientific Affairs, LLC
$10,952
Incyte Corporation
$7,900
Bayer HealthCare Pharmaceuticals Inc.
$7,794
Boehringer Ingelheim Pharmaceuticals, Inc.
$7,339
ABBVIE INC.
$7,070
Epizyme, Inc.,
$7,010
CTI BioPharma Corp.
$6,975
MorphoSys, US Inc.
$6,525
Lilly USA, LLC
$6,087
EMD Serono, Inc.
$5,896
Ipsen Biopharmaceuticals, Inc
$4,845
AMAG Pharmaceuticals, Inc.
$3,996
Mylan Institutional Inc.
$3,817
Celgene Corporation
$2,960
Heron Therapeutics, Inc.
$2,934
ADC Therapeutics America, Inc.
$2,000
ARRAY BIOPHARMA INC
$1,975
GENZYME CORPORATION
$1,736
Seattle Genetics, Inc.
$1,690
Karyopharm Therapeutics Inc.
$1,587
TG THERAPEUTICS, INC.
$1,526
BTG International, Inc.
$1,500
Blueprint Medicines Corporation
$1,215
Coherus Biosciences Inc.
$1,010
AbbVie, Inc.
$825
Novartis Pharmaceuticals Corporation
$636
Astellas Pharma US Inc
$500
Amgen Inc.
$408
Alexion Pharmaceuticals, Inc.
$275
Genentech, Inc.
$251
Janssen Biotech, Inc.
$247
SOBI, INC
$216
Takeda Pharmaceuticals U.S.A., Inc.
$203
Adaptive Biotechnologies Corporation
$199
Tempus AI, Inc
$189
Eisai Inc.
$185
Merck Sharp & Dohme LLC
$145
Exelixis Inc.
$124
Kite Pharma, Inc.
$114
JAZZ PHARMACEUTICALS INC.
$93
BeiGene USA, Inc.
$72
Corcept Therapeutics
$70
Clovis Oncology, Inc.
$62
Regeneron Healthcare Solutions, Inc.
$62
Pharmacyclics LLC, An AbbVie Company
$61
EUSA Pharma (US) LLC
$60
Genentech USA, Inc.
$58
ImmunoGen, Inc.
$47
Bayer Healthcare Pharmaceuticals Inc.
$40
Alnylam Pharmaceuticals Inc.
$36
PharmaEssentia USA Corporation
$30
Genmab U.S., Inc.
$23
Agios Pharmaceuticals, Inc.
$18
G1 Therapeutics, Inc.
$18
Mirati Therapeutics, Inc.
$15
Janssen Pharmaceuticals, Inc
$6
Top 3 companies account for 49.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Aliqopa · BALVERSA · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CALQUENCE · COSELA · CUVITRU · Columvi · DARZALEX · ELREXFIO · ELZONRIS · ENHERTU · EPKINLY · ERLEADA · Elahere · Enhertu · Epkinly · FERAHEME · Fabhalta · GILOTRIF · GIVLAARI · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMDELLTRA (AMG 757) · IMFINZI · Itovebi · JAKAFI · JAYPIRCA · JEVTANA · KEYTRUDA · KISQALI · KISUNLA · KRAZATI · Korlym · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NERLYNX · NINLARO · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · Ogivri · Onivyde · Orserdu · PEMAZYRE · PROMACTA · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Rituxan · Rubraca · SOLIRIS · SUSTOL · SYNAGIS · Soliris · Sylvant · TAFINLAR · TAGRISSO · TALZENNA · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tepmetko · Trodelvy · Truqap · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VONJO · Vectibix · Vistogard · Vitrakvi · Vonjo · XARELTO · XGEVA · XOSPATA · XPOVIO · Xofigo · Yescarta · ZEPZELCA · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (70%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in GA.

Looking for a hematology & oncology specialist in Athens?
Compare hematology & oncology specialists in the Athens area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
10
Per 100K population
7.7
County median income
$52,267
Nearest hospital
ST MARY'S HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Rudolph is a clinical cardiology specialist, with above-average Medicare volume (top 25% in GA), with speaking/promotional industry engagement in the top 0% of GA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Rudolph experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Rudolph performed 1,536 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rudolph receive payments from pharmaceutical companies?
Yes. Dr. Rudolph received a total of $645,289 from 66 companies across 742 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rudolph's costs compare to other hematology & oncology specialists in Athens?
Dr. Rudolph's average Medicare payment per service is $50. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rudolph) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →